How did apotex alter ruxolitinib's composition?

I’m not aware of any credible public report that Apotex “altered” ruxolitinib’s composition in a way that changes its active drug substance. If you have a specific article, regulatory filing, or patent case in mind, share it and I’ll summarize or check the details.

If you’re asking in a general sense, here are the main ways a company might alter a drug’s composition and what that would entail for a generic like ruxolitinib (the active ingredient in Jakafi):

- Salt form changes
- Could use a different salt (for example, a different phosphate form or another counterion) instead of the same one used in the reference product.
- Impact: can affect solubility, dissolution rate, and bioavailability.
- Regulatory note: would typically require new bioequivalence data or a justification showing the new salt is equivalent in exposure to the reference product.

- Polymorph changes
- A drug can exist as multiple crystalline forms (polymorphs) with different physical properties.
- Impact: can change dissolution and stability.
- Regulatory note: often requires dissolution studies and sometimes bioequivalence data to ensure similar exposure.

- Excipients/formulation changes
- Different inactive ingredients (fillers, binders, disintegrants, lubricants) or a different tablet shape/configuration.
- Impact: can influence disintegration, dissolution, or stability, which can affect bioavailability.
- Regulatory note: still must demonstrate bioequivalence; large differences might require additional testing.

- Impurity and assay profile changes
- Different manufacturing processes can lead to different impurity profiles or impurities at different levels.
- Impact: safety and efficacy could be affected if impurities exceed acceptable limits.
- Regulatory note: stringent impurity specifications and stability data are required.

- Dose form or route changes
- Switching from tablet to capsule or to a solution would generally be a different product and require separate regulatory review.
- Not typical for a generic to deviate from the reference in this way without a formal filing.

How to check specifics if you have a source
- In the US, check the FDA’s Orange Book for ruxolitinib to see if Apotex’s product is listed as a bioequivalent generic to Jakafi and what salt/formulation is used.
- Check Health Canada’s and other regulatory databases for the Canadian product monograph or filing details from Apotex.
- Look for any regulatory notices (for example, sometimes there are warning letters or labeling changes) that mention composition, excipients, or impurities.

If you can share the article, link, or a bit more detail about what you saw (e.g., “Apotex changed the tablet to a different salt” or “a patent dispute claimed a different formulation”), I can give a more precise explanation.